ClinicalTrials.gg
CompletedNCT04779307Updated Apr 30, 2026Results posted

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

A Phase 3 interventional study of Vedolizumab in Colitis, Ulcerative, sponsored by Takeda. Completed at 65 sites in 14 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
18th of 38
121 · median 110
Started
2021
with 4 others
Phase 3
14 of 38
3 open now
Registered
27th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 18th largest by enrollment, is one of 5 that started in 2021, is one of 14 in phase 3, and was the 27th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab.

The main aim of the study is to check if participants achieve remission after treatment with vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no or limited signs of disease.

The study is also evaluating side effects of vedolizumab in the children and teenager with moderately to severely active ulcerative colitis.

Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive 1 of 3 doses of vedolizumab once every 8 weeks. They will receive the same dose every time.

Read the detailed description

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat pediatric participants who have moderately to severely active UC. Participants to be enrolled must have failed response to, lost response to, or been intolerant to at least 1 of the current standard of care (SOC) induction and maintenance therapies for UC including immunomodulators (eg, azathioprine [AZA], 6-mercaptopurine [6-MP], methotrexate [MTX]), and tumor necrosis factor-alpha (TNF-α) antagonists (eg, infliximab, adalimumab).

The study will enroll approximately 120 patients.

During the Induction Period participants will receive 3 doses of vedolizumab IV infusion at Day 1, Week 2, and Week 6 based on their weight at Baseline:

  • Participants ≥30 kg, Vedolizumab 300 mg
  • Participants >15 to \<30 kg, Vedolizumab 200 mg
  • Participants 10 to 15 kg, Vedolizumab 150 mg

At Week 14, participants who achieve clinical response will be randomly assigned (by chance, like flipping a coin) in a 1:1 ratio to one of the 2 double-blind dose groups (high dose and low dose), stratified by previous exposure/failure to TNF-α antagonists therapy or naive to TNF-α antagonists therapy, and weight. Participants will receive vedolizumab IV infusions every 8 weeks (Q8W) up to Week 46 during the Maintenance Period as follows:

  • Participants ≥30 kg, Vedolizumab 300 mg (High dose) or 150 mg (Low dose)
  • Participants >15 to \<30 kg, Vedolizumab 200 mg (High dose) or 100 mg (Low dose)
  • Participants 10 to 15 kg, Vedolizumab 150 mg (High dose) or 100 mg (Low dose)

The dose will remain blinded to the participant and study doctor and staff during the study (unless there is an urgent medical need). All participants will be administered vedolizumab via IV infusion. In participants who demonstrate lack of maintenance of clinical response during the Maintenance Period the dose will be escalated in a blinded fashion based on the weight at the time of the worsening of disease. In addition one-time rescue therapy with corticosteroids is allowed during Maintenance period.

This multi-center trial will be conducted worldwide. After the Week 54 visit, participants who are younger than 18 years may be eligible to continue receiving vedolizumab in extension study MLN0002-3029 (NCT05442567). Participants who do not maintain corticosteroid-free clinical response at Week 54 or who discontinue study drug at any time during the induction or maintenance periods of this study will undergo an end of study (EOS) or early termination (ET) visit, as well as a safety visit 18 weeks after the last dose of vedolizumab, in addition these participants would enter study MLN0002-3029 for an observational long-term follow-up (LTFU) period of 2 years after the last dose of study drug in the current study. During the LTFU period, data will be collected either by clinic visit OR, if site attendance is not feasible, by phone call every 6 months.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has moderately to severely active UC, unresponsive or intolerant to their current standard of care (SOC).
  2. Weighs ≥10 kg at the time of screening and enrollment into the study.
  3. Participants with UC diagnosed at least 1 month before screening. Participants with moderately to severely active UC based on a modified Mayo score of 5 to 9 (sum of Mayo endoscopic subscore, stool frequency subscore, and rectal bleeding subscore) with a Mayo endoscopic subscore of ≥2 (with the presence of mucosal friability excluding an endoscopic subscore of 1 and mandating a score of at least 2) at screening endoscopy.
  4. Has failed, lost response to, or been intolerant to treatment with at least 1 of the following agents: (eg, azathioprine [AZA], 6-mercaptopurine [6-MP], methotrexate [MTX]), immunomodulators, and/or tumor necrosis factor alpha (TNF-α) antagonist therapy (eg, infliximab, adalimumab). This includes participants who are dependent on corticosteroids to control symptoms and who are experiencing worsening of disease in the moderate-to-severe range when attempting to wean off corticosteroids.
  5. Has evidence of UC extending proximal to the rectum (i.e., not limited to proctitis), at a minimum.
  6. Has extensive colitis or pancolitis of >8 years' duration or left-sided colitis of >12 years' duration must have documented evidence of a negative surveillance colonoscopy within 12 months before screening.
  7. Participants with vaccinations that are up-to-date based on the countrywide, accepted schedule of childhood vaccines.

Exclusion criteria

Exclusion Criteria:

  1. Has previous exposure to approved or anti-integrins including, but not limited to natalizumab, efalizumab, etrolizumab, or Abrilumab (AMG 181), or mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antagonists or rituximab.
  2. Has received an investigational biologic within 60 days or 5 half-lives before screening (whichever is longer); or an approved biologic or biosimilar agent within 2 weeks before the first dose of study drug or at any time during the screening period.
  3. Has active cerebral/meningeal disease, signs/symptoms or history of progressive multifocal leukoencephalopathy (PML) or any other major neurological disorders including stroke, multiple sclerosis, brain tumor or neurodegenerative disease.
  4. Has had infection (eg, pneumonia, pyelonephritis, coronavirus disease 2019 [COVID-19]) within 30 days prior to first dose of study drug.
  5. Has received any within 30 days prior to first dose of study drug.
  6. Participants who currently require surgical intervention or are anticipated to require surgical intervention for UC during this study.
  7. Has had subtotal or total colectomy or have a jejunostomy, ileostomy, colostomy, ileo-anal pouch, or known fixed stenosis of the intestine.
  8. Participants with a current diagnosis of indeterminate colitis.
  9. Participants with clinical features suggesting monogenic very early onset inflammatory bowel disease.
  10. Participant with active or latent tuberculosis (TB), as evidenced by a diagnostic TB test performed within 30 days of screening or during the screening period that is positive, defined as:

    • Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR
    • A TB skin test reaction ≥5 mm. NOTE: If participants have received Bacillus Calmette-Guérin vaccine then a QuantiFERON TB Gold test should be performed instead of the TB skin test.
  11. Participants with evidence of positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Hepatitis B virus (HBV) immune participants (ie, hepatitis B surface antigen [HBsAg]-negative and hepatitis B antibody-positive) may, however, be included. Note: If a participant tests negative for HBsAg, but positive for HBcAb, the participant would be considered eligible if the absence of HBV DNA is confirmed by HBV DNA polymerase chain reaction reflex testing performed in the central laboratory.

    Participants with chronic virus (HCV) (ie, positive HCV antibody [HCVAb] and HCV RNA). Note: Subjects who are HCVAb-positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCV RNA at least 12 weeks before baseline]).

  12. The participant has evidence of dysplasia or history of other than a successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix.
  13. Has positive stool studies for ova and/or parasites or stool culture at screening visit.
  14. Has positive Clostridioides difficile (C difficile) stool test at screening visit.

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Induction Period: Participants ≥30 kg, Vedolizumab 300 mg

    Vedolizumab 300 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of ≥30 kg are included in this arm.

    Drug: Vedolizumab

  • Experimental
    Induction Period: Participants >15 to <30 kg, Vedolizumab 200 mg

    Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of \>15 to \<30 kg are included in this arm.

    Drug: Vedolizumab

  • Experimental
    Induction Period: Participants 10 to 15 kg, Vedolizumab 150 mg

    Vedolizumab 150 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of 10 to 15 kg are included in this arm.

    Drug: Vedolizumab

  • Experimental
    Maintenance Period: Participants ≥30 kg, Vedolizumab 300 mg

    Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.

    Drug: Vedolizumab

  • Experimental
    Maintenance Period: Participants ≥30 kg, Vedolizumab 150 mg

    Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.

    Drug: Vedolizumab

  • Experimental
    Maintenance Period: Participants >15 to <30 kg, Vedolizumab 200 mg

    Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.

    Drug: Vedolizumab

  • Experimental
    Maintenance Period: Participants >15 to <30 kg, Vedolizumab 100 mg

    Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.

    Drug: Vedolizumab

  • Experimental
    Maintenance Period: Participants 10 to 15 kg, Vedolizumab 150 mg

    Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.

    Drug: Vedolizumab

  • Experimental
    Maintenance Period: Participants 10 to 15 kg, Vedolizumab 100 mg

    Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.

    Drug: Vedolizumab

Interventions

  • Vedolizumab IV infusion.

    Also known as: MLN0002, ENTYVIO, KYNTELES

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score

    Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy). Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.

    Time frame: At Week 54

Secondary outcomes

  1. Percentage of Participants With Clinical Remission at Week 14 Based on Modified Mayo Score

    Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.

    Time frame: At Week 14

  2. Percentage of Participants With Sustained Clinical Remission at Week 54 Based on Modified Mayo Score

    Participants who had clinical remission at Week 14 were analyzed for sustained clinical remission at Week 54. Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.

    Time frame: At Week 54

  3. Percentage of Participants With Sustained Endoscopic Remission at Week 54

    Participants who had endoscopic remission at Week 14 were analyzed for sustained endoscopic remission at Week 54. Mayo endoscopic sub score (MES) was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.

    Time frame: At Week 54

  4. Percentage of Participants With Endoscopic Response at Week 14

    Endoscopic response was defined as a decrease from baseline in the MES \>=1 point. MES was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.

    Time frame: At Week 14

  5. Percentage of Participants With Endoscopic Response at Week 54

    Endoscopic response was defined as a decrease from baseline in the MES \>=1 point. MES was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.

    Time frame: At Week 54

  6. Percentage of Participants With Corticosteroid-free Clinical Remission at Week 54

    Corticosteroid-free clinical remission based on the modified Mayo score was defined as when a participant meets the definition described in the primary endpoint and was off corticosteroids at least 12 weeks prior to and at Week 54 and without presence of any intercurrent event. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.

    Time frame: At Week 54

  7. Percentage of Participants With Clinical Remission at Week 54 Based on Complete Mayo Score

    Clinical remission based on complete Mayo score was a score (inclusive of physician global assessment \[PGA\]) of \<=2 points with no individual sub score \>1 and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Complete Mayo score was a composite index of 4 disease activity variables (stool frequency, rectal bleeding, endoscopy \[modified so that a score of 1 does not include friability\], and PGA sub scores) ranging from 0-12. Higher score indicated more severe disease.

    Time frame: At Week 54

  8. Serum Trough Concentrations of Vedolizumab Over Time

    Serum trough concentration of vedolizumab was reported.

    Time frame: Predose at Week 14 and post dose at Week 54

  9. Percentage of Participants With Positive Anti-vedolizumab Antibodies (AVA)

    AVA positive was defined as a confirmed AVA positive result.

    Time frame: Up to Week 54

  10. Percentage of Participants With Positive Neutralizing AVA

    Positive Neutralizing AVA was defined as a positive result in the neutralizing AVA assay at any visit.

    Time frame: Up to Week 54

  11. Percentage of Participants With Sustained Clinical Response at Week 54 Based on Complete Mayo Score

    Participants who had clinical response at Week 14 were analyzed for sustained clinical response at Week 54. Sustained refers to meeting the specific endpoint criteria at both Week 14 and Week 54. Sustained clinical response is defined as meeting the following criteria at both Week 14 and Week 54: reduction in complete Mayo score of \>=3 points and \>=30% from baseline with an accompanying decrease in rectal bleeding sub score of \>=1 point or absolute rectal bleeding sub score of \<=1 point. Mayo score was an instrument designed to measure disease activity of UC. Complete Mayo score was a composite index of 4 disease activity variables (stool frequency, rectal bleeding, endoscopy \[modified so that a score of 1 does not include friability\], and PGA sub scores) ranging from 0-12. Higher score indicated more severe disease.

    Time frame: At Week 54

  12. Percentage of Participants With Clinical Response up to Week 54 Based on Partial Mayo Score

    Clinical response was where a participant achieved clinical response if they had a reduction of \>=2 points and \>=25% from the baseline partial Mayo score, including a \>=1 point decrease in the Mayo stool frequency sub score and a \>=1 point reduction in the rectal bleeding sub score or absolute rectal bleeding sub score of \<=1 point. Mayo score was an instrument designed to measure disease activity of UC. A partial Mayo score was defined as composite index of 3 disease activity variables (stool frequency, rectal bleeding, and PGA sub scores) that ranged from 0-9 and excluded the endoscopy sub score. Higher score indicates more severe disease.

    Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54

  13. Percentage of Participants With Clinical Remission up to Week 54 Based on Partial Mayo Score

    Clinical remission based on partial Mayo score was defined as a partial Mayo score of \<=2 points and no individual sub score \>1 point. Mayo score was an instrument designed to measure disease activity of UC. A partial Mayo score was defined as composite index of 3 disease activity variables (stool frequency, rectal bleeding, and PGA sub scores) that ranged from 0-9 and excluded the endoscopy sub score. Higher score indicates more severe disease.

    Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54

  14. Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (TESAE), and Adverse Event of Special Interest (AESI)

    A TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug through Week 54 for participants entering the extension study or the final safety visit 18 weeks after their last dose of study drug for those who do not enter the extension study or those who early terminate. A TESAE was defined as an undesirable event that was not present prior to medical treatment or an already present event that worsened either in intensity or frequency following the first dose of study drug, that occurred from the first dose of study drug to the day of last dose of study drug + 126 days. AESI was defined as an AE (serious or nonserious) of medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was appropriate. AESIs include infusion-related reactions and hypersensitivity, serious infection, malignancy, or other (liver injury and progressive multifocal leukoencephalopathy \[PML\]).

    Time frame: From first dose of study drug up to end of follow up (up to 3.7 years)

  15. Change From Baseline in Weight

    Change from baseline in weight was reported.

    Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54

  16. Change From Baseline in Weight Z-score

    Change from baseline in weight Z-score was reported. Weight z-score expresses how an individual's measured weight compares to the expected weight of a reference population of the same age and sex, standardized using population growth charts. It represents the number of standard deviations (SDs) an individual's weight is above or below the mean of the reference population. Z-score was calculated as: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score indicates that the observed value is below (lower than) the reference mean, while a positive Z-score indicates that the observed value is above (higher than) the reference mean.

    Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54

  17. Change From Baseline in Height

    Change from baseline in height was reported.

    Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54

  18. Change From Baseline in Linear Growth Z-score

    Change from baseline in linear growth Z-score were reported. Linear growth Z-score is a standardized measure that describes how far a measured height deviates from the median height of a reference population of the same age and sex based on established growth charts. It is expressed in units of standard deviations (SD). Z-score was calculated as: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score indicates that the observed value is below (lower than) the reference mean, while a positive Z-score indicates that the observed value is above (higher than) the reference mean.

    Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54

  19. Number of Participants With Change From Baseline in Tanner Stage at Week 54

    Tanner stages are used to evaluate growth parameters. They are standardized for age, sex, and pubertal development, with Stage 1 representing the prepubertal stage and Stage 5 representing the fully mature adult stage. It measures Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). The data reported shows shifts in participants' Tanner stages from baseline to Week 54.

    Time frame: At Week 54

07

Results

Posted Apr 30, 2026

Participant flow

The study was conducted across 43 investigative sites in the United States, Asia/Australia, Europe, and Israel from 19 October 2021 to 1 July 2025.

Period 1: Induction (up to 14 Weeks)
Participant flow — Period 1: Induction (up to 14 Weeks)
MilestoneParticipants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mgParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Started3279100
Switched weight group from 10-15kg to >15kg to <30kg weight10000
Switched weight group from >15 to <30kg to >=30kg weight group04000
Treated3279000
Completed2217000
Not completed162100
Withdrew: Adverse event02200
Withdrew: Failure to meet continuation criteria00100
Withdrew: Lack of efficacy041500
Withdrew: Withdrawal by parent/guardian00200
Withdrew: Other10100
Period 2: Maintenance (up to 40 Weeks)
Participant flow — Period 2: Maintenance (up to 40 Weeks)
MilestoneParticipants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mgParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Started0004746
Completed0004331
Not completed000415
Withdrew: Adverse event00010
Withdrew: Lack of efficacy00014
Withdrew: Withdrawal by subject00026
Withdrew: Withdrawal by parent/guardian00001
Withdrew: Failure to meet continuation criteria00001
Withdrew: Protocol deviation00002
Withdrew: Other00001

Outcome measures

PrimaryPercentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score

Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy). Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.

Time frame:
At Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score
percentage of participantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Percentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score51.1 (36.1 to 65.9)43.5 (28.9 to 58.9)
SecondaryPercentage of Participants With Clinical Remission at Week 14 Based on Modified Mayo Score

Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.

Time frame:
At Week 14
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Week 14 Based on Modified Mayo Score
percentage of participantsParticipants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mg
Percentage of Participants With Clinical Remission at Week 14 Based on Modified Mayo Score33.3 (0.8 to 90.6)44.4 (25.5 to 64.7)31.9 (22.5 to 42.5)
SecondaryPercentage of Participants With Sustained Clinical Remission at Week 54 Based on Modified Mayo Score

Participants who had clinical remission at Week 14 were analyzed for sustained clinical remission at Week 54. Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.

Time frame:
At Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Clinical Remission at Week 54 Based on Modified Mayo Score
percentage of participantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Percentage of Participants With Sustained Clinical Remission at Week 54 Based on Modified Mayo Score29.8 (17.3 to 44.9)28.3 (16.0 to 43.5)
SecondaryPercentage of Participants With Sustained Endoscopic Remission at Week 54

Participants who had endoscopic remission at Week 14 were analyzed for sustained endoscopic remission at Week 54. Mayo endoscopic sub score (MES) was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.

Time frame:
At Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Endoscopic Remission at Week 54
percentage of participantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Percentage of Participants With Sustained Endoscopic Remission at Week 5436.2 (22.7 to 51.5)30.4 (17.7 to 45.8)
SecondaryPercentage of Participants With Endoscopic Response at Week 14

Endoscopic response was defined as a decrease from baseline in the MES \>=1 point. MES was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.

Time frame:
At Week 14
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Response at Week 14
percentage of participantsParticipants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mg
Percentage of Participants With Endoscopic Response at Week 1466.7 (9.4 to 99.2)48.1 (28.7 to 68.1)49.5 (38.8 to 60.1)
SecondaryPercentage of Participants With Endoscopic Response at Week 54

Endoscopic response was defined as a decrease from baseline in the MES \>=1 point. MES was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.

Time frame:
At Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Response at Week 54
percentage of participantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Percentage of Participants With Endoscopic Response at Week 5459.6 (44.3 to 73.6)47.8 (32.9 to 63.1)
SecondaryPercentage of Participants With Corticosteroid-free Clinical Remission at Week 54

Corticosteroid-free clinical remission based on the modified Mayo score was defined as when a participant meets the definition described in the primary endpoint and was off corticosteroids at least 12 weeks prior to and at Week 54 and without presence of any intercurrent event. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.

Time frame:
At Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Corticosteroid-free Clinical Remission at Week 54
percentage of participantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Percentage of Participants With Corticosteroid-free Clinical Remission at Week 5456.5 (34.5 to 76.8)27.8 (9.7 to 53.5)
SecondaryPercentage of Participants With Clinical Remission at Week 54 Based on Complete Mayo Score

Clinical remission based on complete Mayo score was a score (inclusive of physician global assessment \[PGA\]) of \<=2 points with no individual sub score \>1 and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Complete Mayo score was a composite index of 4 disease activity variables (stool frequency, rectal bleeding, endoscopy \[modified so that a score of 1 does not include friability\], and PGA sub scores) ranging from 0-12. Higher score indicated more severe disease.

Time frame:
At Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Week 54 Based on Complete Mayo Score
percentage of participantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Percentage of Participants With Clinical Remission at Week 54 Based on Complete Mayo Score53.2 (38.1 to 67.9)43.5 (28.9 to 58.9)
SecondarySerum Trough Concentrations of Vedolizumab Over Time

Serum trough concentration of vedolizumab was reported.

Time frame:
Predose at Week 14 and post dose at Week 54
Reported as:
Mean · microgram/ml (mcg/ml)
Serum Trough Concentrations of Vedolizumab Over Time
microgram/ml (mcg/ml)Participants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
At Week 1416.92 ± 10.27513.26 ± 9.522
At Week 545.97 ± 4.12012.60 ± 7.413
SecondaryPercentage of Participants With Positive Anti-vedolizumab Antibodies (AVA)

AVA positive was defined as a confirmed AVA positive result.

Time frame:
Up to Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-vedolizumab Antibodies (AVA)
percentage of participantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Percentage of Participants With Positive Anti-vedolizumab Antibodies (AVA)2.36.5
SecondaryPercentage of Participants With Positive Neutralizing AVA

Positive Neutralizing AVA was defined as a positive result in the neutralizing AVA assay at any visit.

Time frame:
Up to Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Neutralizing AVA
percentage of participantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Percentage of Participants With Positive Neutralizing AVA02.2
SecondaryPercentage of Participants With Sustained Clinical Response at Week 54 Based on Complete Mayo Score

Participants who had clinical response at Week 14 were analyzed for sustained clinical response at Week 54. Sustained refers to meeting the specific endpoint criteria at both Week 14 and Week 54. Sustained clinical response is defined as meeting the following criteria at both Week 14 and Week 54: reduction in complete Mayo score of \>=3 points and \>=30% from baseline with an accompanying decrease in rectal bleeding sub score of \>=1 point or absolute rectal bleeding sub score of \<=1 point. Mayo score was an instrument designed to measure disease activity of UC. Complete Mayo score was a composite index of 4 disease activity variables (stool frequency, rectal bleeding, endoscopy \[modified so that a score of 1 does not include friability\], and PGA sub scores) ranging from 0-12. Higher score indicated more severe disease.

Time frame:
At Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Clinical Response at Week 54 Based on Complete Mayo Score
percentage of participantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Percentage of Participants With Sustained Clinical Response at Week 54 Based on Complete Mayo Score66.0 (50.7 to 79.1)63.0 (47.5 to 76.8)
SecondaryPercentage of Participants With Clinical Response up to Week 54 Based on Partial Mayo Score

Clinical response was where a participant achieved clinical response if they had a reduction of \>=2 points and \>=25% from the baseline partial Mayo score, including a \>=1 point decrease in the Mayo stool frequency sub score and a \>=1 point reduction in the rectal bleeding sub score or absolute rectal bleeding sub score of \<=1 point. Mayo score was an instrument designed to measure disease activity of UC. A partial Mayo score was defined as composite index of 3 disease activity variables (stool frequency, rectal bleeding, and PGA sub scores) that ranged from 0-9 and excluded the endoscopy sub score. Higher score indicates more severe disease.

Time frame:
At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response up to Week 54 Based on Partial Mayo Score
percentage of participantsParticipants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mg
At Week 266.7 (9.4 to 99.2)37.0 (19.4 to 57.6)39.6 (29.5 to 50.4)
At Week 666.7 (9.4 to 99.2)70.4 (49.8 to 86.2)61.5 (50.8 to 71.6)
At Week 1066.7 (9.4 to 99.2)77.8 (57.7 to 91.4)64.8 (54.1 to 74.6)
At Week 14100 (29.2 to 100)77.8 (57.7 to 91.4)72.5 (62.2 to 81.4)
At Week 2233.3 (0.8 to 90.6)59.3 (38.8 to 77.6)60.4 (49.6 to 70.5)
At Week 300.0 (0.0 to 70.8)74.1 (53.7 to 88.9)59.3 (48.5 to 69.5)
At Week 3833.3 (0.8 to 90.6)63.0 (42.4 to 80.6)58.2 (47.4 to 68.5)
At Week 4633.3 (0.8 to 90.6)70.4 (49.8 to 86.2)56.0 (45.2 to 66.4)
At Week 5433.3 (0.8 to 90.6)70.4 (49.8 to 86.2)57.1 (46.3 to 67.5)
SecondaryPercentage of Participants With Clinical Remission up to Week 54 Based on Partial Mayo Score

Clinical remission based on partial Mayo score was defined as a partial Mayo score of \<=2 points and no individual sub score \>1 point. Mayo score was an instrument designed to measure disease activity of UC. A partial Mayo score was defined as composite index of 3 disease activity variables (stool frequency, rectal bleeding, and PGA sub scores) that ranged from 0-9 and excluded the endoscopy sub score. Higher score indicates more severe disease.

Time frame:
At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission up to Week 54 Based on Partial Mayo Score
percentage of participantsParticipants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mg
At Week 233.3 (0.8 to 90.6)29.6 (13.8 to 50.2)23.1 (14.9 to 33.1)
At Week 666.7 (9.4 to 99.2)59.3 (38.8 to 77.6)48.4 (37.7 to 59.1)
At Week 1066.7 (9.4 to 99.2)55.6 (35.3 to 74.5)59.3 (48.5 to 69.5)
At Week 1466.7 (9.4 to 99.2)77.8 (57.7 to 91.4)65.9 (55.3 to 75.5)
At Week 2233.3 (0.8 to 90.6)59.3 (38.8 to 77.6)58.2 (47.4 to 68.5)
At Week 300.0 (0.0 to 70.8)70.4 (49.8 to 86.2)61.5 (50.8 to 71.6)
At Week 3833.3 (0.8 to 90.6)70.4 (49.8 to 86.2)60.4 (49.6 to 70.5)
At Week 4633.3 (0.8 to 90.6)74.1 (53.7 to 88.9)58.2 (47.4 to 68.5)
At Week 5433.3 (0.8 to 90.6)66.7 (46.0 to 83.5)53.8 (43.1 to 64.4)
SecondaryPercentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (TESAE), and Adverse Event of Special Interest (AESI)

A TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug through Week 54 for participants entering the extension study or the final safety visit 18 weeks after their last dose of study drug for those who do not enter the extension study or those who early terminate. A TESAE was defined as an undesirable event that was not present prior to medical treatment or an already present event that worsened either in intensity or frequency following the first dose of study drug, that occurred from the first dose of study drug to the day of last dose of study drug + 126 days. AESI was defined as an AE (serious or nonserious) of medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was appropriate. AESIs include infusion-related reactions and hypersensitivity, serious infection, malignancy, or other (liver injury and progressive multifocal leukoencephalopathy \[PML\]).

Time frame:
From first dose of study drug up to end of follow up (up to 3.7 years)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (TESAE), and Adverse Event of Special Interest (AESI)
percentage of participantsParticipants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mgParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Participants with at Least One TEAE10077.866.772.363.0
Participants with TESAE014.810.06.410.9
Participants with AESI025.912.210.619.6
SecondaryChange From Baseline in Weight

Change from baseline in weight was reported.

Time frame:
At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Reported as:
Mean · kilograms (kg)
Change From Baseline in Weight
kilograms (kg)Participants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Change at Week 20.50 ± 1.2870.74 ± 1.037
Change at Week 61.04 ± 2.0501.38 ± 1.960
Change at Week 101.56 ± 2.4581.66 ± 2.155
Change at Week 141.93 ± 2.7621.88 ± 2.806
Change at Week 222.40 ± 3.0512.79 ± 3.540
Change at Week 302.97 ± 3.3793.22 ± 4.338
Change at Week 383.93 ± 3.6983.70 ± 4.900
Change at Week 464.40 ± 4.5514.51 ± 4.578
Change at Week 544.56 ± 4.8334.85 ± 5.033
SecondaryChange From Baseline in Weight Z-score

Change from baseline in weight Z-score was reported. Weight z-score expresses how an individual's measured weight compares to the expected weight of a reference population of the same age and sex, standardized using population growth charts. It represents the number of standard deviations (SDs) an individual's weight is above or below the mean of the reference population. Z-score was calculated as: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score indicates that the observed value is below (lower than) the reference mean, while a positive Z-score indicates that the observed value is above (higher than) the reference mean.

Time frame:
At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Reported as:
Mean · Z-score
Change From Baseline in Weight Z-score
Z-scoreParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Change at Week 20.080 ± 0.14070.084 ± 0.1489
Change at Week 60.161 ± 0.25320.164 ± 0.2490
Change at Week 100.227 ± 0.29550.210 ± 0.2799
Change at Week 140.269 ± 0.34790.237 ± 0.3312
Change at Week 220.325 ± 0.37080.347 ± 0.3861
Change at Week 300.410 ± 0.42680.394 ± 0.4892
Change at Week 380.519 ± 0.44250.462 ± 0.5510
Change at Week 460.585 ± 0.52240.570 ± 0.5000
Change at Week 540.609 ± 0.54620.622 ± 0.5570
SecondaryChange From Baseline in Height

Change from baseline in height was reported.

Time frame:
At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Reported as:
Mean · centimeters (cm)
Change From Baseline in Height
centimeters (cm)Participants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Change at Week 20.20 ± 0.4480.27 ± 0.699
Change at Week 60.45 ± 0.6450.39 ± 1.051
Change at Week 100.65 ± 0.8660.85 ± 1.317
Change at Week 141.08 ± 1.0871.14 ± 1.492
Change at Week 221.80 ± 1.6171.82 ± 2.007
Change at Week 302.45 ± 1.9962.59 ± 2.064
Change at Week 383.30 ± 2.3593.07 ± 2.433
Change at Week 463.93 ± 2.8933.76 ± 2.748
Change at Week 544.64 ± 3.2743.99 ± 3.227
SecondaryChange From Baseline in Linear Growth Z-score

Change from baseline in linear growth Z-score were reported. Linear growth Z-score is a standardized measure that describes how far a measured height deviates from the median height of a reference population of the same age and sex based on established growth charts. It is expressed in units of standard deviations (SD). Z-score was calculated as: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score indicates that the observed value is below (lower than) the reference mean, while a positive Z-score indicates that the observed value is above (higher than) the reference mean.

Time frame:
At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Reported as:
Mean · Z-score
Change From Baseline in Linear Growth Z-score
Z-scoreParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Change at Week 20.033 ± 0.07110.040 ± 0.1032
Change at Week 60.072 ± 0.10260.057 ± 0.1457
Change at Week 100.106 ± 0.15320.134 ± 0.2267
Change at Week 140.175 ± 0.18830.186 ± 0.2631
Change at Week 220.290 ± 0.28930.297 ± 0.3682
Change at Week 300.389 ± 0.35750.407 ± 0.3755
Change at Week 380.537 ± 0.45340.490 ± 0.4553
Change at Week 460.629 ± 0.53830.602 ± 0.5154
Change at Week 540.754 ± 0.63410.616 ± 0.5673
SecondaryNumber of Participants With Change From Baseline in Tanner Stage at Week 54

Tanner stages are used to evaluate growth parameters. They are standardized for age, sex, and pubertal development, with Stage 1 representing the prepubertal stage and Stage 5 representing the fully mature adult stage. It measures Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). The data reported shows shifts in participants' Tanner stages from baseline to Week 54.

Time frame:
At Week 54
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Tanner Stage at Week 54
ParticipantsParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54)44
Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54)01
Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54)00
Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54)00
Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54)00
Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54)01
Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54)11
Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54)20
Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54)10
Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54)00
Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54)00
Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54)11
Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54)02
Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54)22
Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54)00
Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54)00
Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54)00
Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54)00
Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54)13
Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54)64
Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54)00
Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54)00
Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54)00
Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54)00
Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54)30
Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54)55
Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54)01
Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54)00
Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54)00
Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54)00
Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54)01
Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54)01
Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54)20
Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54)10
Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54)00
Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54)00
Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54)10
Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54)02
Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54)22
Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54)00
Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54)00
Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54)00
Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54)00
Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54)13
Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54)54
Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54)00
Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54)00
Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54)00
Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54)00
Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54)40
Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54)45
Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54)02
Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54)10
Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54)00
Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54)00
Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54)01
Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54)21
Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54)20
Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54)10
Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54)00
Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54)00
Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54)00
Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54)24
Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54)01
Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54)00
Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54)00
Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54)00
Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54)11
Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54)01
Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54)32
Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54)00
Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54)00
Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54)10
Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54)00
Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54)41
Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54)53
Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54)13
Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54)10
Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54)00
Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54)00
Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54)31
Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54)00
Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54)10
Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54)41
Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54)33
Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54)00
Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54)00
Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54)11
Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54)02
Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54)01
Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54)10
Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54)20
Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54)55
Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54)12
Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54)11
Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54)00
Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54)00
Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54)50
Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54)00
Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54)00
Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54)40
Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54)23
Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54)00
Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54)00
Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54)12
Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54)02
Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54)11
Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54)00
Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54)20
Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54)86
Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54)22
Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54)21
Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54)00
Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54)10
Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54)20
Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54)01
Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54)10
Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54)00
Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54)00
Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54)30
Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54)12
Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54)00
Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54)00
Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54)00
Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54)00
Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54)00
Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54)00
Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54)01
Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54)00
Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54)00
Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54)22

Adverse events

Collected over From first dose of study drug up to end of follow up (up to 3.7 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants 10 to 15 kg: Vedolizumab 150 mg0/3 (0%)0/3 (0%)3/3 (100%)
Participants >15 to <30 kg: Vedolizumab 200 mg0/27 (0%)4/27 (14.8%)16/27 (59.3%)
Participants >=30 kg: Vedolizumab 300 mg0/90 (0%)9/90 (10%)34/90 (37.8%)
Participants With All Weight Groups Combined: Vedolizumab Low Dose0/47 (0%)3/47 (6.4%)28/47 (59.6%)
Participants With All Weight Groups Combined: Vedolizumab High Dose0/46 (0%)5/46 (10.9%)22/46 (47.8%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventParticipants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mgParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
Colitis ulcerativeGastrointestinal disorders0/32/275/900/472/46
PyrexiaGeneral disorders0/32/270/901/470/46
ArthralgiaMusculoskeletal and connective tissue disorders0/31/270/900/470/46
Electrolyte imbalanceMetabolism and nutrition disorders0/31/270/900/470/46
Peripheral swellingGeneral disorders0/31/270/900/470/46
Adenovirus infectionInfections and infestations0/30/270/900/471/46
Cytomegalovirus infectionInfections and infestations0/30/271/900/471/46
Idiopathic intracranial hypertensionNervous system disorders0/30/270/900/471/46
AppendicitisInfections and infestations0/30/270/901/470/46
Dermal cystSkin and subcutaneous tissue disorders0/30/270/901/470/46
Most frequent other events
Showing 10 of 21
Most frequent other events
EventParticipants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mgParticipants With All Weight Groups Combined: Vedolizumab Low DoseParticipants With All Weight Groups Combined: Vedolizumab High Dose
AnaemiaBlood and lymphatic system disorders1/30/274/901/474/46
Gastroenteritis viralInfections and infestations1/30/270/900/470/46
Oral herpesInfections and infestations1/30/271/900/471/46
ProctalgiaGastrointestinal disorders1/30/270/900/470/46
Rectal prolapseGastrointestinal disorders1/30/270/900/471/46
ThrombocytosisBlood and lymphatic system disorders1/32/270/901/470/46
Upper respiratory tract infectionInfections and infestations1/38/2714/9013/478/46
Colitis ulcerativeGastrointestinal disorders0/31/274/904/476/46
PyrexiaGeneral disorders0/33/275/904/474/46
DiarrhoeaGastrointestinal disorders0/30/271/900/474/46

Baseline characteristics

The intent to treat (ITT) analysis set included all enrolled participants for the induction period, defined by when the informed consent form was obtained, and the participant was determined not to be a screen failure. Participants were not required to receive any dose of vedolizumab to be included in the ITT population.

Age, Continuous
Age, Continuous(years)Participants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mgTotal
Mean2.7 ± 0.586.2 ± 2.7813.8 ± 2.2411.9 ± 4.2
Sex: Female, Male
Sex: Female, Male(Participants)Participants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mgTotal
Female2144763
Male1134458
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mgTotal
Hispanic or Latino0123
Not Hispanic or Latino32689118
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants 10 to 15 kg: Vedolizumab 150 mgParticipants >15 to <30 kg: Vedolizumab 200 mgParticipants >=30 kg: Vedolizumab 300 mgTotal
American Indian or Alaska Native0000
Asian0122638
Native Hawaiian or Other Pacific Islander0000
Black or African American0202
White3136480
More than one race0000
Unknown or Not Reported0011
08

Study locations

65 sites
  • Phoenix Childrens Hospital -1919 E Thompson Rd
    Phoenix, Arizona 85016-7710, United States
  • Rady Childrens Hospital San Diego - PIN
    San Diego, California 92123, United States
  • Childrens Center For Digestive Healthcare
    Atlanta, Georgia 30318-4833, United States
  • Advocate Children's Hospital Park Ridge
    Park Ridge, Illinois 60068, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • MNGI Digestive Health PA-Plymouth
    Minneapolis, Minnesota 55413, United States
  • Mayo Clinic - PIN
    Rochester, Minnesota 55905-0001, United States
  • Goryeb Children's Hospital
    Morristown, New Jersey 07960-6136, United States
  • UPMC Children's Hospital of Pittsburgh-120 Lytton Ave
    Pittsburgh, Pennsylvania 15224-1334, United States
  • Texas Childrens Hospital West Campus
    Houston, Texas 77030-2358, United States
  • Carilion Children's Tanglewood Center
    Roanoke, Virginia 24013-2253, United States
  • Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
  • Queensland Childrens Hospital
    South Brisbane, Queensland 4101, Australia
  • Monash Health, Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Royal Children's Hospital Melbourne - PIN
    Parkville, Victoria 3052, Australia
  • UZ Antwerpen
    Edegem, Antwerpen 2650, Belgium
  • Universitair Ziekenhuis Brussel - PIN
    Jette, Brussels Capital 1090, Belgium
  • Universitaire Ziekenhuizen(UZ)Leuven-Campus Gasthuisberg
    Leuven, Vlaams Brabant 3000, Belgium
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2S2, Canada
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Beijing Children's Hospital, Capital Medical University - PIN
    Beijing, Beijing Municipality 100045, China
  • Henan Children's Hospital Zhengzhou Children's Hospital
    Zhengzhou, Henan 450000, China
  • Children's Hospital of Fudan University
    Shanghai, Shanghai Municipality 201102, China
  • The Children's Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Klinika Za Djecje Bolesti Zagreb
    Zagreb, City of Zagreb 10000, Croatia
  • Children's Hospital "Agia Sofia"
    Athens, Attica 115 27, Greece
  • Attikon University General Hospital
    Chaïdári, Attica 124 62, Greece
  • Ippokratio General Hospital of Thessaloniki
    Thessaloniki, 546 42, Greece
  • Clinexpert Gyogycentrum
    Budapest, 1033, Hungary
  • Semmelweis Egyetem
    Budapest, 1085, Hungary
  • Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz
    Miskolc, 3526, Hungary
  • Shaare Zedek Medical Center
    Jerusalem, Jerusalem 91031, Israel
  • Hadassah Medical Center - PPDS
    Jerusalem, Jerusalem 91120, Israel
  • Rambam Medical Center - PPDS
    Haifa, 31096, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Schneider Childrens Medical Center of Israel Petah Tikvah PIN
    Petah Tikva, 49100, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Azienda Ospedaliera Universitaria Federico II
    Naples, Campania 80131, Italy
  • Azienda USL di Bologna
    Bologna, Emilia-Romagna 40133, Italy
  • Azienda Ospedaliera Universitaria Policlinico Umberto I - Universita di Roma La Sapienza
    Rome, Lazio 00161, Italy
  • Fondazione IRCCS San Gerardo dei Tintori - ASST di Monza A. O. San Gerardo
    Monza, Monza E Brianza 20900, Italy
  • Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PIN
    Florence, Tuscany 50139, Italy
  • AOU dell'Universita degli Studi della Campania Luigi Vanvitelli - Piazza Luigi Miraglia, 2
    Naples, 280138, Italy
  • Kurume University Hospital
    Kurume, Hukuoka 830-0011, Japan
  • Juntendo University Hospital
    Bunkyo-Ku, Tokyo 113-8431, Japan
  • National Center for Child Health and Development
    Setagaya-ku, Tokyo 157-8535, Japan
  • Japanese Red Cross Kumamoto Hospital
    Kumamoto, 861-8520, Japan
  • Saitama Children's Medical Center
    Saitama, 330-8777, Japan
  • Uniwersytecki Szpital Dzieciecy
    Krakow, Lesser Poland Voivodeship 30-663, Poland
  • WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, Masovian Voivodeship 00-728, Poland
  • Instytut 'Pomnik - Centrum Zdrowia Dziecka'
    Warsaw, Masovian Voivodeship 04-736, Poland
  • Korczowski Bartosz, Gabinet Lekarski
    Rzeszów, Podkarpackie Voivodeship 35-302, Poland
  • Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II Spsk Nr 6 Sum W Katowicach
    Katowice, Silesian Voivodeship 40-752, Poland
  • Twoja Przychodnia SCM
    Szczecin, West Pomeranian Voivodeship 71-434, Poland
  • SPZOZ Centralny Szpital Kliniczny UM w Lodzi - ul. Pomorska 251
    Lodz, Łódź Voivodeship 91-738, Poland
  • Instytut Centrum Zdrowia Matki Polki
    Lodz, Łódź Voivodeship 93-338, Poland
  • Kyungpook National University Chilgok Hospital
    Daegu, Daegu Gwang'yeogsi 41404, South Korea
  • Gachon University Gil Medical Center
    Seoul, Incheon Gwang'yeogsi 3080, South Korea
  • Samsung Medical Center
    Seoul, Seoul Teugbyeolsi 06351, South Korea
  • Seoul National University Hospital
    Seoul, Seoul Teugbyeolsi 21565, South Korea
  • The Royal London Hospital
    London, London, City of E1 1BB, United Kingdom
  • Great Ormond Street Hospital
    London, London, City of WC1N 3JH, United Kingdom
  • Birmingham Women's and Children's NHS Foundation Trust
    Birmingham, West Midlands B4 6NH, United Kingdom
  • Noahs Ark Childrens Hospital for Wales
    Cardiff, CF14 4XW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2025, 44 months.

Results were first posted in Apr 2026, 9 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 44 months is close to that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2021
First posted
Mar 3, 2021
StartActual
Oct 19, 2021
Primary completionActual
Jul 1, 2025
CompletionActual
Jul 1, 2025
Results first posted
Apr 30, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04779307
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 3, 2021
Start date
Oct 19, 2021
Primary completion
Jul 1, 2025
Completion
Jul 1, 2025
Results posted
Apr 30, 2026
Last update
Apr 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion